Prelude Therapeutics (PRLD) Income from Continuing Operations (2019 - 2026)

Prelude Therapeutics has disclosed Income from Continuing Operations across 8 years of filings, most recently posting 14177000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 14177000.0, up 59.03% year-over-year; the trailing twelve-month figure through Mar 2026 was 84137000.0 (up 39.89% YoY), and the FY2025 annual result was 104566000.0, up 25.16% from the prior year.
• Income from Continuing Operations came in at 14177000.0 for Q1 2026 at Prelude Therapeutics, up from 17348000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 14177000.0 in Q1 2026 to a low of 37379000.0 in Q4 2023.
• The 5-year median for Income from Continuing Operations is 32398000.0 (2023), against an average of 30251411.76.
• Across the five-year window, Income from Continuing Operations plunged 37.88% in 2022 and jumped 59.03% in 2026, its largest moves.
• Prelude Therapeutics' Income from Continuing Operations stood at 33385000.0 in 2022, then slipped by 11.96% to 37379000.0 in 2023, then increased by 9.49% to 33831000.0 in 2024, then soared by 48.72% to 17348000.0 in 2025, then grew by 18.28% to 14177000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 14177000.0 (Q1 2026), 17348000.0 (Q4 2025), and 20418000.0 (Q3 2025), per Business Quant data.